Aikido Pharma (NASDAQ: AIKI) stock was up by only 18% so far this year. Investors seem to be waiting for the study results about its anti-cancer drugs from the company. The company's drug portfolio focuses on the treatment of four cancers, prostate cancer, pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company is developing the pancreatic cancer drug, DHA-dFdC at University of Texas at Austin. The drug overcomes tumor cell resistance to current chemotherapeutic drugs and is well tolerated in preclinical toxicity tests. The company said that the drug has promising indications of becoming the next generation of chemotherapy treatment for advanced pancreatic cancer.
The company has also updated in February on its broad spectrum anti-viral platform compounds with the potential to treat influenza, COVID-19, Ebola and other viral infections. The company is currently testing these new compounds against Influenza virus with testing on SARS-CoV-2 in the near future.
Interestingly, the company has recently withdrawn its S-1 registration statement that was previously filed with the U.S. SEC. The company said that through a series of recent financing transactions, it has sufficient capital to fund research activities, and anticipated that the publication of testing data about its drug research is expected in the second quarter of this year.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.